SS-31, also known as Elamipretide, is a mitochondria-targeted tetrapeptide that improves mitochondrial function and is currently undergoing clinical trials for various diseases, including heart failure and mitochondrial myopathy.

It interacts with cardiolipin, a phospholipid abundant in the inner mitochondrial membrane, and enhances electron transfer, ATP synthesis, and reduces reactive oxygen species (ROS) production.